Clinical Trials
27 trialsNCT03715205 2025-08-29
Keynote-593
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00866684 2025-03-14
PROSKIN
Charite University, Berlin, Germany
Phase 4 Terminated
NCT01926496 2025-03-07
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
LEO Pharma
Phase 4 Completed
NCT05741294 2025-02-20
A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses
Almirall, S.A.
Phase 4 Completed
NCT01794793 2024-10-01
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP
Phase 4 Completed
NCT03327831 2024-06-27
Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses
University of California, Irvine
Phase 4 Completed
NCT01856023 2023-12-05
PROCLIVITY02
Clinigen, Inc.
Phase 4 Terminated
NCT01459666 2022-05-26
Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer
University Hospitals Cleveland Medical Center
Phase 4 Terminated
NCT02866695 2022-03-09
Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
University of California, San Francisco
Phase 4 Completed
NCT02436408 2021-10-28
VISORB
University of Michigan Rogel Cancer Center
Phase 4 Completed
NCT00847912 2021-06-11
VAKCCT
VA Office of Research and Development
Phase 4 Completed
NCT00414765 2021-06-08
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
Novartis
Phase 4 Completed
NCT01000636 2021-05-26
Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT)
Galderma R&D
Phase 4 Completed
NCT03511326 2021-02-18
SESAME 2
Galderma R&D
Phase 4 Completed
NCT02451488 2020-02-10
Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma
Mayo Clinic
Phase 4 Completed
NCT01007448 2019-11-12
Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
Bausch Health Americas, Inc.
Phase 4 Completed
NCT02446223 2019-09-06
Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%
Goldman, Butterwick, Fitzpatrick and Groff
Phase 4 Completed
NCT00695578 2018-12-31
Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy
Wake Forest University Health Sciences
Phase 4 Completed
NCT00696488 2018-09-10
Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population
Wake Forest University Health Sciences
Phase 4 Completed
NCT02716714 2018-04-18
Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis
Korea University
Phase 4 Completed
NCT01053819 2018-02-23
Can We Miss Pigmented Lesions in Psoriasis Patients?
University of Alabama at Birmingham
Phase 4 Completed
NCT02251652 2017-04-26
Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses
Icahn School of Medicine at Mount Sinai
Phase 4 Completed
NCT00774787 2016-11-07
Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses
Rigel Dermatology
Phase 4 Completed
NCT01203878 2014-12-08
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
Tennessee Clinical Research Center
Phase 4 Terminated
NCT00129961 2012-04-11
Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 4 Completed
NCT00324272 2011-08-11
Post-Operative Drainage Following Lymph Node Dissection
Oxford University Hospitals NHS Trust
Phase 4 Completed
NCT00116649 2010-07-20
Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
Graceway Pharmaceuticals, LLC
Phase 4 Completed